<DOC>
	<DOC>NCT00861926</DOC>
	<brief_summary>Double-blind, multinational, multicentre, randomized, 2-arm parallel-group study</brief_summary>
	<brief_title>Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics</brief_title>
	<detailed_description>To compare efficacy of Foster as maintenance therapy plus additional inhalations as reliever with Foster as maintenance plus salbutamol as reliever in asthmatics</detailed_description>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Written signed and dated informed consent obtained. Male or female patients aged ≥ 18 years. A positive reversibility test Patients who experienced at least one severe exacerbation in the 12 months before entry (but not in the last month) Using inhaled corticosteroids (ICS) in monotherapy or using ICS in a fixed or free combination with long acting beta2 agonists (LABA) at a constant dose for two months before screening visit Not fully controlled asthmatics (which means partly controlled or/and uncontrolled patients according to GINA guidelines 2007) in the last month before screening visit Forced expiratory volume in the first second (FEV1) ≥ 60% of predicted for the patient normal value. Non smokers or exsmokers Pregnant or nursing (lactating) women. Women of childbearing potential UNLESS they meet the following definition of postmenopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels &gt;40 mIU/mL or are using one or more of acceptable methods of contraception Body Mass Index (BMI) &gt; 34 kg/m2. Patient with lower respiratory tract infections affecting the patient's asthma within 30 days of the screening visit. Use of systemic steroids in the last month. Patients with other lung diseases such as COPD, cystic fibrosis, interstitial lung diseases or any other clinically or functionally significant lung disorder. Patients who have an uncontrolled respiratory, haematological, immunologic, renal, neurologic, hepatic, endocrinal or other disease. Clinically relevant laboratory abnormalities Patients who have an abnormal QTcF interval value Intolerance or contraindication to treatment with beta2agonists and/or ICS or allergy to any component of the study treatments. Patients treated with slowrelease corticosteroids in the 3 months prior to screening visit. Patients being treated with antiIgE antibodies. Patients treated with LABA or ICS/LABA fixed combination in the 24h before screening visit Severe asthma exacerbation in the last month before screening visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Maintenance and Reliever Treatments</keyword>
</DOC>